ONO oncology：New Immuno
New Immuno
2024年9月17日—ONOfocusesitsresearchononcology,immunology,neurologyandspecialtyresearchwithhighmedicalneedsaspriorityareasfordiscovery ...。其他文章還包含有：「Oncology」、「小野薬品のオンコロジー情報サイト（ONOONCOLOGY...」、「RisingtothechallengesofImmuno」、「オノオンコロジー」、「TurbineEstablishesResearchCollaborationwithOno...」、「ONO」、「Bristol」、「PhaseIStudyofAnti-Pd」
查看更多 離開網站
Oncology
https://us.ono-pharma.com
ONO has been a leader in oncology research for decades, challenging traditional thinking and bringing innovative therapeutics from bench to bedside.
小野薬品のオンコロジー情報サイト（ONO ONCOLOGY ...
https://www.ono-oncology.jp
本ウェブサイトは、医療関係者の方を対象に小野薬品の製品に関する情報などを提供することを目的としています。
Rising to the challenges of Immuno
https://www.ono-pharma.com
Ono today announced that it will begin airing its new commercial “Rising to the challenges of Immuno-Oncology” in Japan from October 2, 2024.
オノオンコロジー
https://p.ono-oncology.jp
胃がん、肺がん、大腸がんなど、各種がんの治療に関する情報や、患者さん、ご家族の心や暮らしをサポートする情報、オプジーボ、カイプロリス、イメンド、ビラフトビ、 ...
Turbine Establishes Research Collaboration with Ono ...
https://turbine.ai
“Ono has a history of developing transformative cancer therapies, including its important role in launching Opdivo (nivolumab), the first ever ...
ONO
https://www.youtube.com
Bristol
https://news.bms.com
“Ono's Prostaglandin E2 receptor antagonist programs offer the potential to develop targeted therapies that counteract the effects of an ...
Phase I Study of Anti-Pd
https://www.annalsofoncology.o
This phase I study investigated the tolerability, safety and pharmacokinetics of ONO-4538 in combination with chemotherapy in Japanese patients with advanced ...